Nextech V Oncology S.C.S. SICAV-SIF 13D and 13G filings for PMV Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-02-14 4:00 pm Sale | 2021-12-31 | 13G | PMV Pharmaceuticals, Inc. PMVP | Nextech V Oncology S.C.S. SICAV-SIF | 1,385,807 3.100% | -1,142,483 (-45.19%) | Filing |
| 2021-02-16 4:00 pm Purchase | 2020-12-31 | 13G | PMV Pharmaceuticals, Inc. PMVP | Nextech V Oncology S.C.S. SICAV-SIF | 2,528,290 5.600% | 2,528,290 (New Position) | Filing |